Literature DB >> 21632749

Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Delphine Pannetier1, Stéphanie Reynard, Marion Russier, Alexandra Journeaux, Noël Tordo, Vincent Deubel, Sylvain Baize.   

Abstract

The events leading to death in severe cases of Lassa fever (LF) are unknown. Fatality seems to be linked to high viremia and immunosuppression, and cellular immunity, rather than neutralizing antibodies, appears to be essential for survival. We previously compared Lassa virus (LV) with its genetically close but nonpathogenic homolog Mopeia virus (MV), which was used to model nonfatal LF. We showed that strong and early activation of antigen-presenting cells (APC) may play a crucial role in controlling infection. Here we developed an in vitro model of dendritic-cell (DC)-T-cell coculture in order to characterize human T-cell responses induced by MV- or LV-infected DCs. Our results show very different responses to infection with LV and MV. MV strongly and durably stimulated CD8(+) and CD4(+) T cells, showing early and high activation, a strong proliferative response, and acquisition of effector and memory phenotypes. Furthermore, robust and functional CD4(+) and CD8(+) cytotoxic T lymphocytes (CTL) were generated. LV, however, induced only weak memory responses. Thus, this study allows an improved understanding of the pathogenesis and immune mechanisms involved in the control of human LV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632749      PMCID: PMC3147965          DOI: 10.1128/JVI.02120-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Induction of primary human CD8+ T lymphocyte responses in vitro using dendritic cells.

Authors:  A L Zarling; J G Johnson; R W Hoffman; D R Lee
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

2.  Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection.

Authors:  Mohammed Alsharifi; Mario Lobigs; Matthias Regner; Eva Lee; Aulikki Koskinen; Arno Müllbacher
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

3.  FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells.

Authors:  Marc Dauer; Katharina Schad; Jan Herten; Jana Junkmann; Christian Bauer; Rosemarie Kiefl; Stefan Endres; Andreas Eigler
Journal:  J Immunol Methods       Date:  2005-07       Impact factor: 2.303

4.  Optimization of a dendritic cell-based assay for the in vitro priming of naïve human CD4+ T cells.

Authors:  Janice M Moser; Emily R Sassano; Del C Leistritz; Jennifer M Eatrides; Sanjay Phogat; Wayne Koff; Donald R Drake
Journal:  J Immunol Methods       Date:  2009-11-17       Impact factor: 2.303

5.  Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts.

Authors:  M D Bowen; C J Peters; S T Nichol
Journal:  Mol Phylogenet Evol       Date:  1997-12       Impact factor: 4.286

6.  Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus.

Authors:  S M Buckley; J Casals
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

7.  Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells.

Authors:  K Schlienger; N Craighead; K P Lee; B L Levine; C H June
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

8.  Priming of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cell responses by dendritic cells loaded with HIV-1 proteins.

Authors:  Xiao-Li Huang; Zheng Fan; Lian Zheng; Luann Borowski; Hongyi Li; Elaine K Thomas; William H Hildebrand; Xiao-Qing Zhao; Charles R Rinaldo
Journal:  J Infect Dis       Date:  2002-12-19       Impact factor: 5.226

9.  A prospective study of the epidemiology and ecology of Lassa fever.

Authors:  J B McCormick; P A Webb; J W Krebs; K M Johnson; E S Smith
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

10.  Macrophage deactivation by interleukin 10.

Authors:  C Bogdan; Y Vodovotz; C Nathan
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  41 in total

1.  Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro.

Authors:  Melissa W Hayes; Ricardo Carrion; Jerritt Nunneley; Andrei E Medvedev; Maria S Salvato; Igor S Lukashevich
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Authors:  Xavier Carnec; Sylvain Baize; Stéphanie Reynard; Laure Diancourt; Valérie Caro; Noel Tordo; Michèle Bouloy
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

3.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

4.  The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses.

Authors:  Marion Russier; Stéphanie Reynard; Xavier Carnec; Sylvain Baize
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

5.  Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response.

Authors:  Stéphanie Reynard; Marion Russier; Alexandra Fizet; Xavier Carnec; Sylvain Baize
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

6.  A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Authors:  Xavier Carnec; Mathieu Mateo; Audrey Page; Stéphanie Reynard; Jimmy Hortion; Caroline Picard; Elsie Yekwa; Laura Barrot; Stéphane Barron; Audrey Vallve; Hervé Raoul; Caroline Carbonnelle; François Ferron; Sylvain Baize
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

7.  A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.

Authors:  Anita K McElroy; Rama S Akondy; Jessica R Harmon; Ali H Ellebedy; Deborah Cannon; John D Klena; John Sidney; Alessandro Sette; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

Review 8.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

9.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

10.  Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus.

Authors:  Andrew M Lee; Justin Cruite; Megan J Welch; Brian Sullivan; Michael B A Oldstone
Journal:  Virology       Date:  2013-05-16       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.